Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension
- PMID: 29588131
- DOI: 10.1016/j.ejvs.2018.02.009
Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension
Abstract
Objectives: To assess protective effects of micronized purified flavonoid fraction (MPFF) on microcirculation in an original chronic model of hind limb venous hypertension with low blood flow in small animals.
Methods: Vein ligatures were performed on male hamsters, as follows: A-right femoral vein; A + B-right femoral vein and its right branch; A + C-right femoral vein and its left branch; A + B + C-right femoral and its right and left branches; D-external right iliac vein. In sham operated groups, similar vascular dissections were performed without ligatures. Superficial (epigastric) and central (jugular) venous pressure evaluations were made during a 10 week period. Hamsters subjected to A + B + C and D ligatures were selected for leukocyte rolling and sticking, functional capillary density (FCD), and venular and arteriolar diameter observations. D ligature was selected to evaluate pharmacological treatment efficacy. MPFF (100 mg/kg), concomitant active flavonoids of MPFF (diosmetin, hesperidin, linarin, and isorhoifolin) (10 mg/kg), diosmin (100 mg/kg) or drug vehicle were administered orally during 2 weeks before vein ligature and 6 weeks thereafter.
Results: A, A + B and A + C models maintained venous return through collaterals. From the 2nd to the 10th weeks after vein ligatures, A + B + C and D models elicited a progressive increase of superficial venous pressure (3.83 ± 0.65 vs. 8.56 ± 0.72 mmHg, p < .001 and 4.13 ± 0.65 vs. 9.35 ± 0.65 mmHg, p < .001, respectively) with significant changes to the microcirculation. As D model significantly increased superficial venous pressure without affecting central venous pressure, it was used to evaluate the long-term effects of treatment. Compared with vehicle, MPFF, concomitant active flavonoids of MPFF, and diosmin, significantly decreased leukocyte-endothelium interaction and prevented FCD reduction. Only MPFF significantly prevented venular enlargement as observed in the vehicle treated group.
Conclusion: MPFF was more effective than diosmin in improving all microvascular variables. The superiority of MPFF over diosmin alone can be explained by the synergistic beneficial effects of the association between diosmin and active flavonoids of MPFF.
Keywords: Chronic venous hypertension model; Concomitant active flavonoids; Diosmin; MPFF; Microcirculation; Venous disease.
Copyright © 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.Int Angiol. 2008 Feb;27(1):81-5. Int Angiol. 2008. PMID: 18277344
-
Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy.Phlebology. 2016 Feb;31(1):50-6. doi: 10.1177/0268355514564414. Epub 2014 Dec 15. Phlebology. 2016. PMID: 25514922
-
Time course of microvalve pathophysiology in high pressure low flow model of venous insufficiency and the role of micronized purified flavonoid fraction.Int Angiol. 2021 Oct;40(5):388-394. doi: 10.23736/S0392-9590.21.04726-X. Epub 2021 Jul 20. Int Angiol. 2021. PMID: 34282857
-
[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].Vnitr Lek. 2015 Sep;61(9):807-14. Vnitr Lek. 2015. PMID: 26465280 Review. Czech.
-
Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.Drugs. 2003;63(1):71-100. doi: 10.2165/00003495-200363010-00005. Drugs. 2003. PMID: 12487623 Review.
Cited by
-
Factors Influencing Venous Remodeling in the Development of Varicose Veins of the Lower Limbs.Int J Mol Sci. 2024 Jan 26;25(3):1560. doi: 10.3390/ijms25031560. Int J Mol Sci. 2024. PMID: 38338837 Free PMC article. Review.
-
Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin.J Clin Aesthet Dermatol. 2024 Jan;17(1):15-23. J Clin Aesthet Dermatol. 2024. PMID: 38298753 Free PMC article. Review.
-
Discovering Potential Compounds for Venous Disease Treatment through Virtual Screening and Network Pharmacology Approach.Molecules. 2023 Dec 5;28(24):7937. doi: 10.3390/molecules28247937. Molecules. 2023. PMID: 38138427 Free PMC article.
-
Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.Adv Ther. 2023 Dec;40(12):5137-5154. doi: 10.1007/s12325-023-02657-0. Epub 2023 Sep 28. Adv Ther. 2023. PMID: 37768506 Free PMC article. Review.
-
VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.Adv Ther. 2023 Nov;40(11):5016-5036. doi: 10.1007/s12325-023-02643-6. Epub 2023 Sep 20. Adv Ther. 2023. PMID: 37728696 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
